In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature

Mycopathologia

Volumn 150, Issue 3, 2001, Pages 101-115

  Espinel Ingroff, Ana ^a   Boyle, Kathleen ^b   Sheehan, Daniel ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Amphotericin B; Antifungal; Fluconazole; Fungicidal; Fungistatic; Itraconazole; Mould; NCCLS; Voriconazole; Yeast

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

COMPARATIVE STUDY; HUMAN; MICROBIOLOGICAL EXAMINATION; PHASE 3 CLINICAL TRIAL; REVIEW; STANDARD;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CLINICAL TRIALS, PHASE III; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; REFERENCE STANDARDS; TRIAZOLES;

ASPERGILLUS; CANDIDA GLABRATA; FUNGI; FUSARIUM; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; PHAEOACREMONIUM PARASITICUM; PHIALOPHORA; SCEDOSPORIUM PROLIFICANS; SPOROTHRIX SCHENCKII; TEREBRANTIA; ZYGOMYCETES;

EID: 0034944963     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010954803886     Document Type: Review

References (55)

1. International conference for the development of a consensus on the management and prevention of severe candidal infections
2. Emergence of cryptococcal disease: Epidemiologic perspectives 100 years after its discovery
3. Itraconazole resistance in Aspergillus fumigatus
4. The emerging role of Fusarium infections in patients with cancer
5. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature
6. Candidiasis: The emergence of a novel species. Candida dubliniensis
7. Invasive aspergillosis caused by Aspergillus ustus: Case report and review
8. Disseminated Aspergillus ustus infection following cardiac surgery
9. National surveillance of nosocomial bloodstream infections due to Candida albicans: Frequency of occurrence and antifungal susceptibility and the SCOPE program
10. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
11. High prevalence of antifungal resistance in Candida spp. from patients with AIDS
12. Resistant candidiasis
13. Disseminated trichosporonosis resistant to amphotericin B
14. Amphotericin B: 30 Years of clinical use
15. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia
16. Lipid formulations of amphotericin B: Clinical efficacies and toxicities
17. The pharmacokinetics and safety of voriconazole following intravenous to oral dose escalation regimens
18. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B
19. Comparative in vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum
20. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain
21. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents
22. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
23. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin
24. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species
25. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
26. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients
27. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
28. Short communication: In vitro antifungal activity of six drugs against 13 clinical isolates of Ochroconis gallopava
29. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
30. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species
31. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
32. In vitro evaluation of voriconazole against some clinically important fungi
33. In vitro activity of voriconazole against selected fungi
34. In vitro testing of susceptibilities of filamentous Ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications
35. In vitro amphotericin B resistance in clinical isolates of Aspergillus Terreus, with a head-to-head comparison to voriconazole
36. Organism-dependent fungicidal activities of azoles
37. Detection of Candida Dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary chromagar Candida screening and susceptibility testing of isolates
38. Optimizing voriconazole susceptibility testing of Candida: Effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility
39. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
40. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
41. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
42. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
43. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
44. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
45. Effects of voriconazole on Candida glabrata in vitro
46. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients
47. In vitro activities of voriconazole (UK-109,496) against fluconzole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
48. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans
49. Voriconazole against fluconazole-susceptible and resistant Candida isolates: In vitro efficacy compares with that of itraconazole and ketoconazole
50. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates
51. In vitro activity of voriconazole against Candida species
52. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease
53. In vitro fungicidal activities of voriconazole, itraconzole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi